Aliases & Classifications for Hypogonadism, Male

MalaCards integrated aliases for Hypogonadism, Male:

Name: Hypogonadism, Male 57
Male Hypogonadism 36 29
Testicular Hypogonadism 70
Hypogonadism Male 54

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive


HPO:

31
hypogonadism, male:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM® 57 241100
KEGG 36 H02027
MedGen 41 C0151721
UMLS 70 C0151721

Summaries for Hypogonadism, Male

OMIM® : 57 Familial male hypogonadism is a highly heterogeneous category from which some disorders such as Reifenstein syndrome (312300), Kallmann syndrome (see 308700), isolated gonadotropin deficiency, and some other entities can be separated. The presence of an autosomal recessive form is suggested by the occurrence of parental consanguinity (Nowakowski and Lenz, 1961). (241100) (Updated 20-May-2021)

MalaCards based summary : Hypogonadism, Male, also known as male hypogonadism, is related to gynecomastia and hypogonadism. An important gene associated with Hypogonadism, Male is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are Metabolism of proteins and Peptide hormone metabolism. The drugs Methyltestosterone and Testosterone undecanoate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and liver, and related phenotypes are micropenis and hypospadias

KEGG : 36 Hypogonadism in male patients is characterized by a deficiency in testosterone - a critical hormone for sexual, cognitive, and body function and development. Low testosterone levels may be due to testicular, hypothalamic, or pituitary abnormalities.

Related Diseases for Hypogonadism, Male

Diseases related to Hypogonadism, Male via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 gynecomastia 30.2 LEP KLK3
2 hypogonadism 29.5 LHCGR LHB LEP
3 pseudohermaphroditism 29.5 LHCGR LHB
4 bone resorption disease 29.5 LEP BGLAP
5 insulin-like growth factor i 29.3 LEP BGLAP
6 hypogonadotropic hypogonadism 29.3 LHCGR LHB LEP
7 infertility 29.2 LHCGR LHB LEP
8 leydig cell hypoplasia, type i 11.2
9 ichthyosis and male hypogonadism 11.1
10 hypogonadism, male, with mental retardation and skeletal anomalies 11.1
11 alstrom syndrome 11.0
12 myotonic dystrophy 2 11.0
13 impotence 10.3
14 osteoporosis 10.2
15 bone mineral density quantitative trait locus 8 10.2
16 bone mineral density quantitative trait locus 15 10.2
17 infant gynecomastia 10.2
18 hypogonadotropic hypogonadism 7 with or without anosmia 10.1
19 testicular disease 10.1
20 isolated gonadotropin-releasing hormone deficiency 10.1
21 body mass index quantitative trait locus 11 10.1
22 body mass index quantitative trait locus 9 10.1
23 body mass index quantitative trait locus 8 10.1
24 body mass index quantitative trait locus 1 10.1
25 body mass index quantitative trait locus 4 10.1
26 body mass index quantitative trait locus 10 10.1
27 body mass index quantitative trait locus 7 10.1
28 body mass index quantitative trait locus 12 10.1
29 body mass index quantitative trait locus 14 10.1
30 body mass index quantitative trait locus 18 10.1
31 body mass index quantitative trait locus 19 10.1
32 sexual disorder 10.1
33 muscular atrophy 10.1
34 azoospermia 10.0
35 estrogen excess 10.0
36 polycythemia 10.0
37 type 2 diabetes mellitus 9.9
38 schistosoma mansoni infection, susceptibility/ 9.9
39 cryptorchidism, unilateral or bilateral 9.9
40 hyperprolactinemia 9.9
41 schistosomiasis 9.9
42 oligospermia 9.9
43 hypothyroidism 9.9
44 ichthyosis 9.9
45 hyperinsulinism 9.9
46 prostate disease 9.9
47 liver cirrhosis 9.9
48 pituitary gland disease 9.9
49 myotonic dystrophy 9.9
50 anorchia 9.9

Graphical network of the top 20 diseases related to Hypogonadism, Male:



Diseases related to Hypogonadism, Male

Symptoms & Phenotypes for Hypogonadism, Male

Human phenotypes related to Hypogonadism, Male:

31
# Description HPO Frequency HPO Source Accession
1 micropenis 31 HP:0000054
2 hypospadias 31 HP:0000047
3 testicular atrophy 31 HP:0000029
4 gynecomastia 31 HP:0000771
5 male hypogonadism 31 HP:0000026

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
G U:
hypospadias
male hypogonadism
small penis
normal-sized testes

Misc:
markedly diminished secondary sexual characteristics

Thorax:
gynecomastia

Clinical features from OMIM®:

241100 (Updated 20-May-2021)

GenomeRNAi Phenotypes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.62 LHB LHCGR

MGI Mouse Phenotypes related to Hypogonadism, Male:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 8.92 BGLAP LEP LHB LHCGR

Drugs & Therapeutics for Hypogonadism, Male

Drugs for Hypogonadism, Male (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
3
Testosterone enanthate Approved Phase 4 315-37-7 9416
4
Testosterone Approved, Investigational Phase 4 58-22-0 6013
5
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
6 Testosterone 17 beta-cypionate Phase 4
7 Androgens Phase 4
8 insulin Phase 4
9 Insulin, Globin Zinc Phase 4
10 Estrogen Antagonists Phase 4
11 Estrogen Receptor Antagonists Phase 4
12 Estrogens Phase 4
13 Aromatase Inhibitors Phase 4
14 Follicle Stimulating Hormone Phase 4
15 Hormones Phase 4
16 Hormone Antagonists Phase 4
17 Anabolic Agents Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19
Coal tar Approved Phase 3 8007-45-2
20
Metformin Approved Phase 3 657-24-9 14219 4091
21 Hypoglycemic Agents Phase 3
22
Dihydrotachysterol Approved Phase 2 67-96-9 5281010 5311071
23
Finasteride Approved Phase 2 98319-26-7 57363
24
Sodium citrate Approved, Investigational Phase 2 68-04-2
25
tannic acid Approved Phase 1, Phase 2 1401-55-4
26
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
28
Enclomiphene Investigational Phase 2 15690-57-0
29
Dihydrotestosterone Illicit, Investigational Phase 2 521-18-6 10635
30 5-alpha Reductase Inhibitors Phase 2
31 Citrate Phase 2
32 Clomiphene Phase 2
33 Estrogen Receptor Modulators Phase 2
34 Zuclomiphene Phase 2
35 Pharmaceutical Solutions Phase 2
36
Inositol Approved, Investigational, Withdrawn 87-89-8
37
Menotropins Approved 9002-68-0, 61489-71-2 5360545
38
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
39 Trace Elements
40 Nutrients
41 Vitamin B9
42 Vitamin B Complex
43 Folate
44 Micronutrients
45 Vitamins
46 Chorionic Gonadotropin

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
2 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Completed NCT03203681 Phase 4 Natesto
3 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Completed NCT02959853 Phase 4 Anastrazole
4 A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™) Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
5 A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections: A Phase IV, Prospective, Randomized, Non-Blinded, Multi-Institutional Study Recruiting NCT04439799 Phase 4 Testosterone Cypionate 200 MG/ML;Intranasal Testosterone
6 A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of Vogelxo(R) on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy Recruiting NCT04558567 Phase 4 Vogelxo
7 An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Administration With Marketed Testosterone Products Recruiting NCT04456296 Phase 4 Aveed Injectable Product, Fortesta or Testim
8 A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism Unknown status NCT01786473 Phase 3 Testogel 1%;Placebo
9 Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed NCT01403116 Phase 3 Oral testosterone undecanoate;topical testosterone gel
10 Phase III, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU)in Hypogonadal Men Completed NCT01765179 Phase 3 Oral testosterone undecanoate
11 A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males Completed NCT01703741 Phase 3 Testosterone Gel (FE 999093)
12 A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males Completed NCT01665599 Phase 3 Testosterone gel (FE 999303)
13 A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males Completed NCT02149264 Phase 3 Testosterone gel (FE 999303)
14 A 6 Month, Open Label, Ambulatory Blood Pressure Monitoring (ABPM) Extension Study Completed NCT04467697 Phase 3 SOV2012-F1
15 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men Completed NCT03868059 Phase 3 LPCN 1021
16 A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne) Completed NCT03198728 Phase 3 SOV2012-F1;AndroGel
17 Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men. Completed NCT03242590 Phase 3 LPCN 1021
18 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men. Completed NCT03242408 Phase 3 LPCN 1021
19 An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males Completed NCT00522431 Phase 3 Testosterone
20 The Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI). Completed NCT00413244 Phase 3 AndroGel 5 Grams;Placebo
21 Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application Completed NCT01228071 Phase 3 testosterone gel 2%
22 A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days Completed NCT01446042 Phase 3 Testosterone;Testosterone
23 Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men Completed NCT01699178 Phase 3 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
24 Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men Completed NCT02081300 Phase 3 Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
25 Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism Completed NCT02514629 Phase 3 Placebo;Metformin;Testosterone Undecanoate;Metformin + Testosterone Undecanoate
26 A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer. Completed NCT00965341 Phase 3 Testosterone;Placebo
27 A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging (35mg/Day or 70 mg/Day), Randomized, Study of Cutaneous Dihydrotestosterone (DHT)-Gel (0.7% Hydroalcoholic Gel) in Older Hypogonadal Males Ages 55-80 Years: Effect on Body Composition, Libido, and Physical and Sexual Functioning Unknown status NCT00163566 Phase 2 Dihydrotestosterone (0.7%) in hydroalcoholic gel
28 Phase II, Repeat Dose, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Completed NCT00695110 Phase 2 Oral testosterone undecanoate (TU) (300 mg T equivalents/dose);Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose);Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food);Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
29 Phase IIa, Pilot, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Completed NCT02697188 Phase 2 Testosterone undecanoate;Testosterone enanthate
30 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride
31 A Phase 2 Open-Label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes (1.25, 2.50 and 3.75 mL) of Testosterone Gel 2% (FE 999303) Equivalent to 23, 46 And 70 mg of Testosterone in Hypogonadal Males Completed NCT01370369 Phase 2 Testosterone gel (FE 99903)
32 A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone Completed NCT01904734 Phase 2 Clomiphene
33 A Randomized Double Blinded Placebo Controlled Trial Between Anastrozole and Clomiphene to Evaluate Improvement in Hypogonadal Symptoms and Erectile Function Using ADAM, IIEF and EHS Validated Scales Completed NCT03933618 Phase 2 Anastrozole 1mg;Clomiphene Citrate 25mg;Placebo - Cap
34 A Phase 2, Open-Label, Sequential Dose Escalation Study in Adult Hypogonadal Males to Evaluate the Pharmacokinetics of Three Volumes of FE 999303 (Testosterone Gel), Applied to the Shoulder/Upper Arm, Using an Applicator Compared With Hand Application Completed NCT01464879 Phase 2 Testosterone Gel (FE 999303)
35 A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males Completed NCT02222558 Phase 2 TSX-002
36 A Phase II Randomised, Two-Way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered-Dose (MD) Lotion Doses in Hypogonadal Male Subjects Completed NCT00372008 Phase 2 Testosterone
37 Phase II Study of the Effect of Food With Various Levels of Fat on the Pharmacokinetics of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men Completed NCT00924612 Phase 2 Oral testosterone undecanoate (containing 300 mg T)
38 Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men. Completed NCT00911586 Phase 2 Testosterone undecanoate
39 Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects. Completed NCT02380755 Phase 2 Clomiphene Citrate;Placebo
40 Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency Recruiting NCT04301765 Phase 2 testosterone 1.62% gel
41 Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer Recruiting NCT04049331 Phase 2 Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
42 A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Terminated NCT03335254 Phase 1, Phase 2 TSX-011
43 A Study to Assess Post-collection Conversion of Testosterone Undecanoate (TU) to Testosterone in Blood From Men Receiving Oral TU Collected Into Different Types of Sample Tubes Completed NCT03973840 Phase 1 Testosterone Undecanoate
44 A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males Completed NCT01346319 Phase 1 ABT-SLV361;placebo
45 A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-TREATMENT SINGLE-DOSE, CROSS-OVER STUDY, 2-PART DESIGN TO EVALUATE THE BIOEQUIVALENCE AND TOLERABILITY OF TESTOSTERONE CYPIONATE FOLLOWING INTRAMUSCULAR (IM) INJECTION IN HEALTHY HYPOGONADAL MALE SUBJECTS Completed NCT03792477 Phase 1
46 A Multiple Dose Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of 5 g Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males Completed NCT01133548 Phase 1 Testosterone Gel 1.62%;Testosterone Gel 1.62%
47 A Phase 1, Randomised, Open-label, 2-cohort, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Native Oral Testosterone Formulation (DITEST) in the Fed and Fasted State and Compared to Testosterone Undecanoate in Adult Men With Primary or Secondary Hypogonadism Completed NCT02966652 Phase 1 DITEST;Testosterone undecanoate
48 D-chiroinositol Administration for Testosterone Level Improvement in Hypogonadal Males Completed NCT04708249
49 Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males Before and After Pharmacological Castration Completed NCT03541395 GnRH antagonist
50 Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male (ADAM) Completed NCT03282682

Search NIH Clinical Center for Hypogonadism, Male

Genetic Tests for Hypogonadism, Male

Genetic tests related to Hypogonadism, Male:

# Genetic test Affiliating Genes
1 Male Hypogonadism 29

Anatomical Context for Hypogonadism, Male

MalaCards organs/tissues related to Hypogonadism, Male:

40
Pituitary, Bone, Liver, Prostate, Testes, Testis, Heart

Publications for Hypogonadism, Male

Articles related to Hypogonadism, Male:

(show top 50) (show all 765)
# Title Authors PMID Year
1
Genetic aspects in male hypogonadism. 61 57
13729828 1961
2
Is the disruption of an N-myristoyltransferase (NMT2) associated with hypoplastic testes? 57
17568424 2007
3
Familial hypogonadism. 57
13177549 1954
4
A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected sister. 54 61
18508780 2008
5
Testosterone replacement therapy in male hypogonadism. 61 54
12906378 2003
6
Luteinizing hormone receptor mutations in disorders of sexual development and cancer. 54 61
10704433 2000
7
Effects of gonadotropin and testosterone treatments on plasma leptin levels in male patients with idiopathic hypogonadotropic hypogonadism and Klinefelter's syndrome. 61 54
9660087 1998
8
Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism. 54 61
9466329 1997
9
Effect of testosterone on bone in hypogonadal males. 61 54
1528131 1992
10
Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol. 61
33718653 2021
11
Male hypogonadism and general practitioners in the UK. How to increase case recognition, without compromising diagnostic accuracy? 61
33655569 2021
12
YouTube as a Patient Education Resource for Male Hypogonadism and Testosterone Therapy. 61
33752104 2021
13
Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes. 61
33735389 2021
14
Testosterone metabolites differentially regulate obesogenesis and fat distribution. 61
33307216 2021
15
Pathophysiology of NASH in endocrine diseases. 61
33449917 2021
16
Insights into the Regulation on Proliferation and Differentiation of Stem Leydig Cells. 61
33598893 2021
17
Is serum PSA a predictor of male hypogonadism? Testing the hypothesis. 61
33587836 2021
18
Importance of total and measured free testosterone in diagnosis of male hypogonadism: immunoassay versus mass spectrometry in a population of healthy young/middle-aged blood donors. 61
32474765 2021
19
Correlation Between Testosterone-Replacement Treatment and Lower Urinary Tract Symptoms. 61
33504130 2021
20
Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism. 61
33420743 2021
21
Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review. 61
33488103 2021
22
SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. 61
32369678 2021
23
Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate. 61
33466340 2021
24
Worse progression of COVID-19 in men: Is testosterone a key factor? 61
32524732 2021
25
Health status is related to testosterone, estrone and body fat: moving to functional hypogonadism in adult men with HIV. 61
33112262 2021
26
Infertility considerations in klinefelter syndrome: From origin to management. 61
33358481 2020
27
Bilateral Testicular Epidermoid Cysts in a Man with Klinefelter Syndrome: A Case Report. 61
33274173 2020
28
Re: Treatment of Male Hypogonadism Partially Reverses Oxidative Stress in Patients with Hypogonadism. 61
32960708 2020
29
An isolated hypogonadotropic hypogonadism male with a novel de novoFGFR1 mutation fathered a normal son evidenced by prenatal genetic diagnosis. 61
32990989 2020
30
Hypergonadotropic Hypogonadism: Management Of Infertility. 61
33138760 2020
31
Impact of Dehydroepiandrosterone (DHEA) on Bone Mineral Density and Bone Mineral Content in a Rat Model of Male Hypogonadism. 61
33238425 2020
32
Late-onset Hypogonadism: Bone health. 61
32469467 2020
33
Implementation of a Pilot Pharmacist Testosterone Therapy Management Service. 61
30791810 2020
34
Endosialin defines human stem Leydig cells with regenerative potential. 61
32951040 2020
35
Bardet-Biedl syndrome and related disorders in Japan. 61
32451492 2020
36
Age-Related Male Hypogonadism and Cognitive Impairment in the Elderly: Focus on the Effects of Testosterone Replacement Therapy on Cognition. 61
33081371 2020
37
Lifestyle, metabolic disorders and male hypogonadism - A one-way ticket? 61
32707080 2020
38
Effect of exogenous glucocorticoids on male hypogonadism. 61
32765851 2020
39
Treatment of male hypogonadism partially reverses oxidative stress in patients with hypogonadism. 61
32448821 2020
40
Subclinical male hypogonadism. 61
32969626 2020
41
Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. 61
32981295 2020
42
Male hypogonadism: therapeutic choices and pharmacological management. 61
33000619 2020
43
Association between prostate-specific antigen and serum testosterone: A systematic review and meta-analysis. 61
32329181 2020
44
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. 61
32937772 2020
45
Defining hypogonadism in male partners of couples with unexplained infertility. 61
32861256 2020
46
Testosterone is sequestered in dysfunctional adipose tissue, modifying androgen-responsive genes. 61
32203110 2020
47
Testosterone replacement therapy in insulin-sensitive hypogonadal men restores phosphatidylcholine levels by regulation of arachidonic acid metabolism. 61
32491269 2020
48
[Testosterone replacement treatment in older people with and without co-morbidities]. 61
32377774 2020
49
Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial. 61
32213659 2020
50
Does follicle stimulating hormone really prevent male hypogonadism in infertile patients? 61
32571110 2020

Variations for Hypogonadism, Male

Expression for Hypogonadism, Male

Search GEO for disease gene expression data for Hypogonadism, Male.

Pathways for Hypogonadism, Male

GO Terms for Hypogonadism, Male

Cellular components related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.46 LHB LEP KLK3 BGLAP
2 Golgi lumen GO:0005796 8.96 LHB BGLAP
3 extracellular space GO:0005615 8.92 LHB LEP KLK3 BGLAP

Biological processes related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.32 LEP BGLAP
2 male gonad development GO:0008584 9.26 LHCGR LHB
3 response to nutrient levels GO:0031667 9.16 LEP BGLAP
4 response to activity GO:0014823 8.96 LEP BGLAP
5 hormone-mediated signaling pathway GO:0009755 8.62 LHCGR LHB

Molecular functions related to Hypogonadism, Male according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 LHB LEP

Sources for Hypogonadism, Male

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....